Novel germ line mutation p53-P177R in adult adrenocortical carcinoma producing neuron-specific enolase as a possible marker

Japanese Journal of Clinical Oncology

Volumn 40, Issue 8, 2010, Pages 815-818

  Ide, Hisamitsu ^a   Terado, Yuichi ^b   Tokiwa, Shino ^a   Nishio, Kojiro ^a   Saito, Keisuke ^a   Isotani, Shuji ^a   Kamiyama, Yutaka ^a   Muto, Satoru ^a   Imamura, Tetsuo ^a   Horie, Shigeo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adernocortical carcinoma; Mutation; Neuron specific enolase; p53

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; MITOTANE; NEURON SPECIFIC ENOLASE; PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CHEMICAL ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; ENZYME BLOOD LEVEL; ENZYME SPECIFICITY; ENZYME SYNTHESIS; FEMALE; GENETIC ANALYSIS; GENOME ANALYSIS; GERM LINE; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; SCREENING;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENES, P53; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; NEPHRECTOMY; PHOSPHOPYRUVATE HYDRATASE; RETROPERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955257983     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq045     Document Type: Article

References (10)

1. Roman S. Adrenocortical carcinoma. Curr Opin Oncol 2006;18:36-42.
2. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006;91:14-21.
3. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol2003;169:5-11.
4. Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007;8:343-8.
5. Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, et al. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene 1999;18:3970-8.
6. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66.
7. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
8. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5.
9. Miettinen M. Neuroendocrine differentiation in adrenocortical carcinoma. New immunohistochemical findings supported by electron microscopy. Lab Invest 1992;66:169-74.
10. Harris SL, Levine AJ. The p53 pathway: positive negative feedback loops. Oncogene 2005;24:2899-908.